DUBLIN--(BUSINESS WIRE)--The "Global Respiratory Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Respiratory Partnering 2012 to 2018 provides the full collection of Respiratory disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.
The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyze and benchmark the value of current deals.
- Trends in Respiratory dealmaking in the biopharma industry since 2012
- Analysis of Respiratory deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Respiratory deal contract documents
- Comprehensive access to over 3500 Respiratory deal records
- The leading Respiratory deals by value since 2012
- Most active Respiratory dealmakers since 2012
In Global Respiratory Partnering 2012 to 2018, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
Specific therapy indication
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Respiratory dealmaking
Chapter 3 - Financial deal terms for Respiratory partnering
Chapter 4 - Leading Respiratory deals and dealmakers
Chapter 5 - Respiratory contract document directory
Chapter 6 - Respiratory dealmaking by therapeutic target
For more information about this report visit https://www.researchandmarkets.com/research/5hh48k/global?w=4